These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 23670521

  • 1. Role of ¹⁸F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer.
    Chondrogiannis S, Marzola MC, Ferretti A, Maffione AM, Rampin L, Grassetto G, Nanni C, Colletti PM, Rubello D.
    Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1356-64. PubMed ID: 23670521
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?
    Castellucci P, Fuccio C, Rubello D, Schiavina R, Santi I, Nanni C, Allegri V, Montini GC, Ambrosini V, Boschi S, Martorana G, Marzola MC, Fanti S.
    Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):55-63. PubMed ID: 20848281
    [Abstract] [Full Text] [Related]

  • 4. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S, Coronado-Poggio M, García-Vicente AM, García-Garzón JR, Alonso-Farto JC, de la Jara AC, Maldonado-Suárez A, Rodríguez-Fernández A.
    BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
    [Abstract] [Full Text] [Related]

  • 5. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
    Beheshti M, Haim S, Zakavi R, Steinmair M, Waldenberger P, Kunit T, Nader M, Langsteger W, Loidl W.
    J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
    [Abstract] [Full Text] [Related]

  • 6. 11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT.
    Ceci F, Castellucci P, Graziani T, Schiavina R, Brunocilla E, Mazzarotto R, Ntreta M, Lodi F, Martorana G, Fanti S.
    Eur J Nucl Med Mol Imaging; 2014 May; 41(5):878-86. PubMed ID: 24346416
    [Abstract] [Full Text] [Related]

  • 7. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
    Castellucci P, Ceci F, Graziani T, Schiavina R, Brunocilla E, Mazzarotto R, Pettinato C, Celli M, Lodi F, Fanti S.
    J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
    Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F, Franceschelli A, Martorana G, Manferrari F, Fanti S.
    J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
    [Abstract] [Full Text] [Related]

  • 11. Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial.
    Ceci F, Herrmann K, Castellucci P, Graziani T, Bluemel C, Schiavina R, Vollmer C, Droll S, Brunocilla E, Mazzarotto R, Buck AK, Fanti S.
    Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2222-31. PubMed ID: 25182750
    [Abstract] [Full Text] [Related]

  • 12. (11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy.
    Ceci F, Castellucci P, Mamede M, Schiavina R, Rubello D, Fuccio C, Ambrosini V, Boschi S, Martorana G, Fanti S.
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(2):149-55. PubMed ID: 23151910
    [Abstract] [Full Text] [Related]

  • 13. Detection Efficacy of Hybrid 68Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria.
    Einspieler I, Rauscher I, Düwel C, Krönke M, Rischpler C, Habl G, Dewes S, Ott A, Wester HJ, Schwaiger M, Maurer T, Eiber M.
    J Nucl Med; 2017 Jul; 58(7):1081-1087. PubMed ID: 28209912
    [Abstract] [Full Text] [Related]

  • 14. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer.
    Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C, Montorsi F, Reske SN, Thalmann GN.
    Eur Urol; 2011 Jan; 59(1):51-60. PubMed ID: 20869161
    [Abstract] [Full Text] [Related]

  • 15. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy.
    Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V, Cozzarini C, Di Muzio N, Rigatti P, Fazio F, Messa C.
    Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):301-9. PubMed ID: 19756592
    [Abstract] [Full Text] [Related]

  • 16. (18)F-choline PET/CT for early detection of metastases in biochemical recurrence following radical prostatectomy.
    Kjölhede H, Ahlgren G, Almquist H, Liedberg F, Lyttkens K, Ohlsson T, Bratt O.
    World J Urol; 2015 Nov; 33(11):1749-52. PubMed ID: 25824540
    [Abstract] [Full Text] [Related]

  • 17. The ability of 18F-choline PET/CT to identify local recurrence of prostate cancer.
    Evangelista L, Cimitan M, Hodolič M, Baseric T, Fettich J, Borsatti E.
    Abdom Imaging; 2015 Oct; 40(8):3230-7. PubMed ID: 26428685
    [Abstract] [Full Text] [Related]

  • 18. (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.
    Graziani T, Ceci F, Castellucci P, Polverari G, Lima GM, Lodi F, Morganti AG, Ardizzoni A, Schiavina R, Fanti S.
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1971-9. PubMed ID: 27277279
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of extraprostatic disease in the staging of prostate cancer by F-18 choline PET/CT: can PSA and PSA density help in patient selection?
    Calabria F, Chiaravalloti A, Tavolozza M, Ragano-Caracciolo C, Schillaci O.
    Nucl Med Commun; 2013 Aug; 34(8):733-40. PubMed ID: 23680652
    [Abstract] [Full Text] [Related]

  • 20. First imaging results of an intraindividual comparison of (11)C-acetate and (18)F-fluorocholine PET/CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy.
    Buchegger F, Garibotto V, Zilli T, Allainmat L, Jorcano S, Vees H, Rager O, Steiner C, Zaidi H, Seimbille Y, Ratib O, Miralbell R.
    Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):68-78. PubMed ID: 24104592
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.